Zeltia Group (18494051.MA) Fails to Win U.K. Backing for Ovarian Cancer Drug
3/11/2011 6:33:17 AM
Bloomberg -- Zeltia SA (ZEL)’s Yondelis failed to win the recommendation of the U.K.’s health-cost agency as a treatment for ovarian cancer, even after the company offered to limit the expense of the medicine.
comments powered by